Outlook Therapeutics reports Q3 2026 results, says FDA approved Lytenava
Outlook Therapeutics said it released third-quarter fiscal 2026 results and hosted a call, while management highlighted FDA approval of Lytenava for wet AMD in the U.S.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
OTLK outlook Therapeutics - lytenava expected to be available to U.S. patients before year-end
OTLK outlook Therapeutics - lytenava expected to be available to U.S. patients before year-end